Details of the Drug Combination

General Information of Drug Combination (ID: DCJ4B8X)

Drug Combination Name
OTX-015 Ruxolitinib
Indication
Disease Entry Status REF
Hodgkin lymphoma Investigative [1]
Component Drugs OTX-015   DMI8RG1 Ruxolitinib   DM7Q98D
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: L-1236
Zero Interaction Potency (ZIP) Score: 11.606
Bliss Independence Score: 10.347
Loewe Additivity Score: 1.364
LHighest Single Agent (HSA) Score: 4.613

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of OTX-015
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1/2 [2]
Myelodysplastic syndrome 2A37 Phase 1 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
OTX-015 Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bromodomain-containing protein 4 (BRD4) TTRA6BO BRD4_HUMAN Modulator [12]
Bromodomain and extraterminal domain protein (BET) TTE4BSY NOUNIPROTAC Inhibitor [13]
Bromodomain-containing protein 2 (BRD2) TTDP48B BRD2_HUMAN Modulator [12]
------------------------------------------------------------------------------------
OTX-015 Interacts with 147 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Coiled-coil domain-containing protein 154 (CCDC154) OTFGNMNP CC154_HUMAN Decreases Expression [11]
Sodium-dependent phosphate transport protein 3 (SLC17A2) OT5U4CFD NPT3_HUMAN Decreases Expression [11]
Protein arginine N-methyltransferase 5 (PRMT5) OTF6IGJS ANM5_HUMAN Decreases Expression [14]
Syntaphilin (SNPH) OTL6XBFA SNPH_HUMAN Increases Expression [11]
Calpain-5 (CAPN5) OTQ8QM7K CAN5_HUMAN Increases Expression [11]
Prominin-1 (PROM1) OTBHV8NX PROM1_HUMAN Decreases Expression [15]
Adhesion G protein-coupled receptor B2 (ADGRB2) OTOCY7XY AGRB2_HUMAN Increases Expression [11]
Uncharacterized protein KIAA0513 (KIAA0513) OT7AVTFB K0513_HUMAN Increases Expression [11]
Tetraspanin-1 (TSPAN1) OTZQPIYK TSN1_HUMAN Decreases Expression [11]
Histone H2B type 1-K (H2BC12) OTQ8V0KG H2B1K_HUMAN Increases Expression [16]
Receptor activity-modifying protein 2 (RAMP2) OTGQXLH5 RAMP2_HUMAN Decreases Expression [11]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-2 (PLCH2) OTYERO80 PLCH2_HUMAN Decreases Expression [11]
Integrin alpha-10 (ITGA10) OTM0V5AO ITA10_HUMAN Decreases Expression [11]
Cytochrome P450 7B1 (CYP7B1) OTIKFYP6 CP7B1_HUMAN Increases Expression [11]
Slit homolog 2 protein (SLIT2) OTLS2RJ4 SLIT2_HUMAN Increases Expression [11]
Protein HEXIM1 (HEXIM1) OTBK7278 HEXI1_HUMAN Increases Expression [16]
Apolipoprotein L3 (APOL3) OT95SQHR APOL3_HUMAN Decreases Expression [11]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases Expression [11]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [17]
Erythropoietin (EPO) OTZ90CN4 EPO_HUMAN Decreases Expression [11]
Inhibin alpha chain (INHA) OT7HWCO3 INHA_HUMAN Decreases Expression [11]
Galectin-2 (LGALS2) OTY08TMQ LEG2_HUMAN Decreases Expression [11]
Protein S100-A9 (S100A9) OTOARHCS S10A9_HUMAN Increases Expression [11]
Histone H2B type 1-J (H2BC11) OTGM083T H2B1J_HUMAN Affects Expression [16]
Complement component C8 alpha chain (C8A) OTIJ65J4 CO8A_HUMAN Decreases Expression [11]
Glutathione S-transferase A1 (GSTA1) OTA7K5XA GSTA1_HUMAN Decreases Expression [11]
Glutathione S-transferase Mu 1 (GSTM1) OTSBF2MO GSTM1_HUMAN Decreases Expression [15]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Affects Cleavage [18]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [17]
Serine/threonine-protein kinase pim-1 (PIM1) OTWEKXTU PIM1_HUMAN Decreases Expression [17]
Glucose-6-phosphate 1-dehydrogenase (G6PD) OT300SMK G6PD_HUMAN Increases Expression [11]
Plastin-2 (LCP1) OTK61F2A PLSL_HUMAN Decreases Expression [11]
Leukemia inhibitory factor (LIF) OTO46S5S LIF_HUMAN Decreases Expression [11]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [15]
Tyrosine aminotransferase (TAT) OT2CJ91O ATTY_HUMAN Decreases Expression [11]
Interleukin-1 receptor antagonist protein (IL1RN) OT308CBE IL1RA_HUMAN Decreases Expression [11]
Glutathione hydrolase 1 proenzyme (GGT1) OTYDA1Z7 GGT1_HUMAN Decreases Expression [11]
Inter-alpha-trypsin inhibitor heavy chain H1 (ITIH1) OTSXJGQF ITIH1_HUMAN Decreases Expression [11]
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) OT0DH40W AL5AP_HUMAN Decreases Expression [11]
Alanine--glyoxylate aminotransferase (AGXT) OTIPTH3Q AGT1_HUMAN Decreases Expression [11]
Glycerol-3-phosphate dehydrogenase , cytoplasmic (GPD1) OTQW7TMB GPDA_HUMAN Decreases Expression [11]
Cathepsin S (CTSS) OT3PXIPM CATS_HUMAN Decreases Expression [11]
Proteasome subunit beta type-8 (PSMB8) OTW5XGMF PSB8_HUMAN Decreases Expression [11]
Glutathione S-transferase theta-1 (GSTT1) OTRFMWBK GSTT1_HUMAN Decreases Expression [15]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [15]
Ribonuclease 4 (RNASE4) OTA5SZLC RNAS4_HUMAN Decreases Expression [11]
Alpha-L-iduronidase (IDUA) OTTQQ7FN IDUA_HUMAN Increases Expression [11]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [16]
Proteasome subunit beta type-10 (PSMB10) OTURUR9B PSB10_HUMAN Decreases Expression [11]
Reduced folate transporter (SLC19A1) OTWB0BTO S19A1_HUMAN Decreases Expression [18]
Sodium- and chloride-dependent glycine transporter 1 (SLC6A9) OTHRUON2 SC6A9_HUMAN Decreases Expression [11]
Mannan-binding lectin serine protease 1 (MASP1) OTWWCNZP MASP1_HUMAN Decreases Expression [11]
Aldo-keto reductase family 1 member D1 (AKR1D1) OTBDJ6RL AK1D1_HUMAN Decreases Expression [11]
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 (FUT6) OTBZUQ7F FUT6_HUMAN Decreases Expression [11]
Ephrin-B2 (EFNB2) OT0DCUOM EFNB2_HUMAN Increases Expression [11]
Huntingtin-associated protein 1 (HAP1) OT6SG0JQ HAP1_HUMAN Increases Expression [11]
Protein ripply3 (RIPPLY3) OT1HK35I DSCR6_HUMAN Decreases Expression [11]
T-box transcription factor TBX4 (TBX4) OTW58FG4 TBX4_HUMAN Decreases Expression [11]
Transmembrane protease serine 3 (TMPRSS3) OT0GTO1Z TMPS3_HUMAN Decreases Expression [11]
Claudin-2 (CLDN2) OTRF3D6Y CLD2_HUMAN Decreases Expression [11]
Sestrin-3 (SESN3) OTJRY1Y5 SESN3_HUMAN Increases Expression [16]
Inhibin beta E chain (INHBE) OTOI2NYG INHBE_HUMAN Decreases Expression [11]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN) OTOWDUNT PTEN_HUMAN Increases Expression [15]
Histone H4 (H4C1) OTB71W46 H4_HUMAN Affects Expression [16]
Glypican-5 (GPC5) OT8NR7GC GPC5_HUMAN Increases Expression [11]
Microtubule-associated protein 1A (MAP1A) OTHO8K43 MAP1A_HUMAN Increases Expression [11]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [17]
Perilipin-5 (PLIN5) OTV8G50L PLIN5_HUMAN Increases Expression [11]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [17]
Schlafen family member 5 (SLFN5) OTT1AESL SLFN5_HUMAN Increases Expression [11]
Protein mab-21-like 4 (MAB21L4) OT4FRKXR MB214_HUMAN Decreases Expression [11]
Protein disulfide-isomerase A2 (PDIA2) OTC2WMXS PDIA2_HUMAN Decreases Expression [11]
Serine/threonine-protein kinase PAK 1 (PAK1) OT17LZNZ PAK1_HUMAN Decreases Expression [11]
Dehydrogenase/reductase SDR family member 2, mitochondrial (DHRS2) OTFHWIY8 DHRS2_HUMAN Increases Expression [11]
N-myc-interactor (NMI) OTYVG3NM NMI_HUMAN Decreases Expression [11]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Expression [15]
GRB2-related adapter protein (GRAP) OTO1P7YX GRAP_HUMAN Decreases Expression [11]
Potassium voltage-gated channel subfamily C member 3 (KCNC3) OT811KOM KCNC3_HUMAN Increases Expression [11]
Dihydropyrimidinase-related protein 3 (DPYSL3) OTINJV20 DPYL3_HUMAN Increases Expression [11]
Lymphocyte antigen 6D (LY6D) OTXCR0SB LY6D_HUMAN Decreases Expression [11]
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (PDE3A) OTKUW1WT PDE3A_HUMAN Decreases Expression [11]
Bromodomain-containing protein 3 (BRD3) OTRT44ZG BRD3_HUMAN Decreases Expression [16]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Decreases Expression [15]
Alpha-internexin (INA) OT1D33T4 AINX_HUMAN Increases Expression [11]
Transcription factor NF-E2 45 kDa subunit (NFE2) OTLM94BI NFE2_HUMAN Decreases Expression [11]
POU domain class 2-associating factor 1 (POU2AF1) OTOO6WHL OBF1_HUMAN Decreases Expression [11]
Histone H2B type 2-E (H2BC21) OT0FDCUC H2B2E_HUMAN Increases Expression [16]
Protein phosphatase 1J (PPM1J) OTM6GDJJ PPM1J_HUMAN Increases Expression [11]
Uncharacterized protein C9orf152 (C9ORF152) OTOGLK0I CI152_HUMAN Decreases Expression [11]
Solute carrier family 35 member F1 (SLC35F1) OTRXHR2P S35F1_HUMAN Increases Expression [11]
Low-density lipoprotein receptor class A domain-containing protein 1 (LDLRAD1) OTG1GL9H LRAD1_HUMAN Decreases Expression [11]
Protein THEMIS2 (THEMIS2) OTI1OBLN THMS2_HUMAN Increases Expression [11]
Terminal nucleotidyltransferase 5C (TENT5C) OTOWVQ4O TET5C_HUMAN Increases Expression [11]
FERM and PDZ domain-containing protein 2 (FRMPD2) OT8OM5MA FRPD2_HUMAN Decreases Expression [11]
Actin-binding LIM protein 2 (ABLIM2) OT62KOXF ABLM2_HUMAN Increases Expression [11]
Protein FAM171B (FAM171B) OT4DJHCM F171B_HUMAN Increases Expression [11]
Monofunctional C1-tetrahydrofolate synthase, mitochondrial (MTHFD1L) OTV01EFP C1TM_HUMAN Decreases Expression [16]
Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 (ENPP7) OTWOBMQ9 ENPP7_HUMAN Decreases Expression [11]
Lipocalin-15 (LCN15) OT9YXMIL LCN15_HUMAN Decreases Expression [11]
Lysophospholipase D GDPD3 (GDPD3) OTOHM9QM GDPD3_HUMAN Decreases Expression [11]
Activity-regulated cytoskeleton-associated protein (ARC) OTN2QQPG ARC_HUMAN Increases Expression [11]
Armadillo-like helical domain-containing protein 4 (ARMH4) OT25GBJM ARMD4_HUMAN Increases Expression [11]
E3 ubiquitin-protein ligase TRIM50 (TRIM50) OTXA2IXF TRI50_HUMAN Decreases Expression [11]
Organic anion transporter 7 (SLC22A9) OTO4BJCC S22A9_HUMAN Decreases Expression [11]
Dynein regulatory complex subunit 7 (DRC7) OTGURR1R DRC7_HUMAN Decreases Expression [11]
E3 ubiquitin-protein ligase TRIM22 (TRIM22) OTJBLG5R TRI22_HUMAN Decreases Expression [11]
Heparan sulfate glucosamine 3-O-sulfotransferase 5 (HS3ST5) OTOB6Z3F HS3S5_HUMAN Decreases Expression [11]
Dermatan-sulfate epimerase-like protein (DSEL) OTVNQD3I DSEL_HUMAN Increases Expression [11]
N-acetylglutamate synthase, mitochondrial (NAGS) OTITB7DO NAGS_HUMAN Decreases Expression [11]
Protein mab-21-like 3 (MAB21L3) OTX0I0V0 MB213_HUMAN Decreases Expression [11]
Mixed lineage kinase domain-like protein (MLKL) OTDSLC81 MLKL_HUMAN Decreases Expression [11]
Arrestin domain-containing protein 4 (ARRDC4) OTINJ0FX ARRD4_HUMAN Increases Expression [11]
Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe (LFNG) OTPSUBN2 LFNG_HUMAN Increases Expression [11]
Transcription factor MafA (MAFA) OTBCA105 MAFA_HUMAN Increases Expression [11]
DEP domain-containing mTOR-interacting protein (DEPTOR) OTCBP1BT DPTOR_HUMAN Decreases Expression [11]
Secreted and transmembrane protein 1 (SECTM1) OT5500CF SCTM1_HUMAN Decreases Expression [11]
Cholesterol transporter ABCA5 (ABCA5) OT4B9D92 ABCA5_HUMAN Increases Expression [11]
Neurogranin (NRGN) OTVGE10W NEUG_HUMAN Increases Expression [11]
Liver-expressed antimicrobial peptide 2 (LEAP2) OTUOPIS5 LEAP2_HUMAN Decreases Expression [11]
Dapper homolog 3 (DACT3) OTSNQ55G DACT3_HUMAN Increases Expression [11]
Hepatitis A virus cellular receptor 1 (HAVCR1) OT184CRZ HAVR1_HUMAN Decreases Expression [11]
Carboxypeptidase B2 (CPB2) OTPIL8IE CBPB2_HUMAN Decreases Expression [11]
Apoptosis-inducing factor 3 (AIFM3) OTSWKCAO AIFM3_HUMAN Decreases Expression [11]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Decreases Expression [11]
Ghrelin O-acyltransferase (MBOAT4) OT2PWOF9 MBOA4_HUMAN Decreases Expression [11]
Endosomal/lysosomal proton channel TMEM175 (TMEM175) OT6DUIYC TM175_HUMAN Increases Expression [11]
Guanine nucleotide-binding protein-like 3 (GNL3) OTILGYO4 GNL3_HUMAN Decreases Expression [15]
Hydroxycarboxylic acid receptor 1 (HCAR1) OT5ZSESQ HCAR1_HUMAN Decreases Expression [11]
Keratin-associated protein 3-1 (KRTAP3-1) OTRWUHTE KRA31_HUMAN Decreases Expression [11]
2-aminomuconic semialdehyde dehydrogenase (ALDH8A1) OTINY3MW AL8A1_HUMAN Decreases Expression [11]
Regulating synaptic membrane exocytosis protein 4 (RIMS4) OTHZMO8Y RIMS4_HUMAN Increases Expression [11]
Src-like-adapter 2 (SLA2) OTNVE666 SLAP2_HUMAN Decreases Expression [11]
Protein TANC2 (TANC2) OTDXY7PX TANC2_HUMAN Increases Expression [11]
Glycerol-3-phosphate acyltransferase 1, mitochondrial (GPAM) OTR1XD9B GPAT1_HUMAN Decreases Expression [11]
Ras-related protein Rab-6B (RAB6B) OT5N57RK RAB6B_HUMAN Increases Expression [11]
Cytokine-inducible SH2-containing protein (CISH) OT8T5NYL CISH_HUMAN Decreases Expression [11]
Transmembrane protein 74B (TMEM74B) OTM7QFEC TM74B_HUMAN Decreases Expression [11]
Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (PAG1) OTFOJUIQ PHAG1_HUMAN Increases Expression [11]
Rhomboid-related protein 2 (RHBDL2) OTJPJ8N6 RHBL2_HUMAN Decreases Expression [11]
Sphingomyelin phosphodiesterase 3 (SMPD3) OTHQBETH NSMA2_HUMAN Increases Expression [11]
Dynein axonemal heavy chain 17 (DNAH17) OT4G6E70 DYH17_HUMAN Decreases Expression [11]
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase (CYP8B1) OTRI4UR1 CP8B1_HUMAN Decreases Expression [11]
Protein EFR3 homolog B (EFR3B) OTVKWU2L EFR3B_HUMAN Increases Expression [11]
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B gamma isoform (PPP2R2C) OTXK0SDM 2ABG_HUMAN Decreases Expression [11]
Ankyrin repeat and SOCS box protein 4 (ASB4) OTI4AFZL ASB4_HUMAN Decreases Expression [11]
Choline-phosphate cytidylyltransferase B (PCYT1B) OTMGVT01 PCY1B_HUMAN Decreases Expression [11]
Lymphatic vessel endothelial hyaluronic acid receptor 1 (LYVE1) OTL0459Z LYVE1_HUMAN Decreases Expression [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 147 DOT(s)
Indication(s) of Ruxolitinib
Disease Entry ICD 11 Status REF
Essential thrombocythemia 3B63.1Z Approved [5]
High-risk myelofibrosis 2A20.2 Approved [6]
Myelofibrosis 2A22 Approved [7]
Myeloproliferative neoplasm 2A20 Approved [8]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [9]
Pancreatic cancer 2C10 Phase 3 [6]
Atopic dermatitis EA80 Phase 1/2 [10]
Vitiligo ED63.0 Phase 1/2 [10]
Ruxolitinib Interacts with 5 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Modulator [19]
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Modulator [19]
Urokinase plasminogen activator surface receptor (PLAUR) TTPRL03 UPAR_HUMAN Inhibitor [20]
HUMAN janus kinase 1 (JAK-1) TTWKB01 JAK1_HUMAN Inhibitor [21]
HUMAN janus kinase 2 (JAK-2) TT0F5HE JAK2_HUMAN Inhibitor [21]
------------------------------------------------------------------------------------
Ruxolitinib Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Mitogen-activated protein kinase 14 (MAPK14) OT5TCO3O MK14_HUMAN Increases ADR [22]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT02303782) A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT). U.S. National Institutes of Health.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8359).
4 Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
8 Ruxolitinib FDA Label
9 Incyte begins Phase III trial of ruxolitinib to treat Covid-19. 20.April.2020.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells. PLoS One. 2022 Apr 29;17(4):e0266966. doi: 10.1371/journal.pone.0266966. eCollection 2022.
12 Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. Haematologica. 2018 Dec;103(12):2049-2058. doi: 10.3324/haematol.2018.191684. Epub 2018 Aug 3.
15 OTX015 Epi-Drug Exerts Antitumor Effects in Ovarian Cancer Cells by Blocking GNL3-Mediated Radioresistance Mechanisms: Cellular, Molecular and Computational Evidence. Cancers (Basel). 2021 Mar 25;13(7):1519. doi: 10.3390/cancers13071519.
16 OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. Int J Cancer. 2016 Nov 1;139(9):2047-55. doi: 10.1002/ijc.30256. Epub 2016 Jul 30.
17 Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 Jan 15;9(2):4. doi: 10.1038/s41408-018-0165-5.
18 Hijacking the E3?Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22(6):755-63. doi: 10.1016/j.chembiol.2015.05.009. Epub 2015 Jun 4.
19 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
20 Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.Cell Cycle. 2014;13(12):1958-69.
21 The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393.
22 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.